EFG Asset Management North America Corp. Has $5.83 Million Stock Holdings in Halozyme Therapeutics, Inc. $HALO

EFG Asset Management North America Corp. reduced its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 23.9% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 79,436 shares of the biopharmaceutical company’s stock after selling 25,003 shares during the period. EFG Asset Management North America Corp. owned approximately 0.07% of Halozyme Therapeutics worth $5,825,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of HALO. DLD Asset Management LP bought a new stake in shares of Halozyme Therapeutics during the second quarter worth $650,250,000. Arrowstreet Capital Limited Partnership increased its holdings in Halozyme Therapeutics by 127.8% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 2,541,181 shares of the biopharmaceutical company’s stock worth $132,192,000 after purchasing an additional 1,425,674 shares in the last quarter. LSV Asset Management raised its stake in shares of Halozyme Therapeutics by 40.2% in the 2nd quarter. LSV Asset Management now owns 1,255,240 shares of the biopharmaceutical company’s stock valued at $65,298,000 after purchasing an additional 360,049 shares during the period. Royal London Asset Management Ltd. lifted its holdings in shares of Halozyme Therapeutics by 122.3% in the second quarter. Royal London Asset Management Ltd. now owns 1,101,912 shares of the biopharmaceutical company’s stock valued at $57,321,000 after purchasing an additional 606,236 shares in the last quarter. Finally, Qube Research & Technologies Ltd bought a new stake in shares of Halozyme Therapeutics in the second quarter valued at about $51,295,000. Institutional investors own 97.79% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on HALO. Wall Street Zen lowered Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, December 6th. HC Wainwright reiterated a “buy” rating and issued a $90.00 price objective on shares of Halozyme Therapeutics in a report on Friday, December 19th. Morgan Stanley reduced their target price on shares of Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating for the company in a report on Monday, October 20th. TD Cowen raised their target price on shares of Halozyme Therapeutics from $79.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. Finally, Zacks Research lowered shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. Eight investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $78.80.

Insiders Place Their Bets

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $70.25, for a total value of $140,500.00. Following the sale, the director owned 40,123 shares in the company, valued at $2,818,640.75. This represents a 4.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Cortney Caudill sold 4,263 shares of Halozyme Therapeutics stock in a transaction that occurred on Saturday, November 1st. The stock was sold at an average price of $65.19, for a total value of $277,904.97. Following the transaction, the chief operating officer owned 12,737 shares of the company’s stock, valued at $830,325.03. This represents a 25.08% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 45,661 shares of company stock valued at $3,139,257 over the last 90 days. 2.90% of the stock is currently owned by insiders.

Halozyme Therapeutics Price Performance

Shares of HALO opened at $69.87 on Tuesday. The company has a current ratio of 1.59, a quick ratio of 1.37 and a debt-to-equity ratio of 1.59. The company’s fifty day simple moving average is $68.76 and its 200 day simple moving average is $68.11. Halozyme Therapeutics, Inc. has a 1-year low of $47.50 and a 1-year high of $79.50. The company has a market cap of $8.22 billion, a price-to-earnings ratio of 14.71, a PEG ratio of 0.30 and a beta of 0.94.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $1.72 EPS for the quarter, beating analysts’ consensus estimates of $1.63 by $0.09. The company had revenue of $354.26 million during the quarter, compared to the consensus estimate of $339.18 million. Halozyme Therapeutics had a net margin of 47.91% and a return on equity of 156.95%. The company’s quarterly revenue was up 22.1% on a year-over-year basis. During the same quarter last year, the firm posted $1.27 EPS. On average, research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.